It is administered under medical supervision as an infusion, typically over a 60-hour time frame.
It belongs to a class of drugs known asneuroactive steroid gamma-aminobutyric acids(GABAs).
Zulresso is available as a solution for intravenous infusion, and its active ingredient is brexanolone.
Fat Camera / Getty Images
Zulresso is currently only available through a program called Zulresso Risk Evaluation and Mitigation Strategy (Zulresso REMS).
What is the most important information I should know about Zulresso?
Postpartum depression is a common condition that affects women of all ages across the world.
Postpartum depression is a mental condition that occurs after childbirth.
You must register for the program before this medication can be administered to you.
This is because of the risk of excessive sedation and loss of consciousness associated with using this medication.
Patients with renal diseases, especially end-stage renal disease should avoid using Zulresso.
According to the manufacturer, no contraindications with other medication have been reported while using Zulresso.
Zulresso is not approved for anyone who is under the age of 18.
Allergic Reactions
In rare cases, some people might experience an allergic reaction when using Zulresso.
When the infusion is resumed they might lower the dosage.
This solution is required to be diluted before being administered to patients.
If stored at room temperature, the medication will only be viable for 12 hours.
An unopened vial of the concentrated solution can be stored at room temperature away from direct sunlight.
Before administration, the vial should be closely inspected.
Five infusion bags are typically prepared for the 60-hour period it takes to administer the medication.
Side Effects of Zulresso
Zulresso has been linked to some side effects in women.
There is also an increased risk of experiencing suicidal thoughts when using Zulresso.
If you or someone you know is receiving Zulresso, look out for changes in moods and behaviors.
Tell your healthcare provider immediately if you notice any of these symptoms.
If you are having suicidal thoughts, contact theNational Suicide Prevention Lifelineat988for support and assistance from a trained counselor.
If you or a loved one are in immediate danger, call 911.
For more mental health resources, see ourNational Helpline Database.
Research shows that with breastfeeding women, the medication can be transferred into the breastmilk.
The active ingredient in Zulresso is brexanolone which is aschedule IV controlled substance.
This means that it has the potential to be abused or for a dependency on the medication to develop.
Ko JY.Trends in Postpartum Depressive Symptoms 27 States, 2004, 2008, and 2012.
MMWR Morb Mortal Wkly Rep. 2017;66.
2019;39(11):1105-1112.
U.S. Food and Drug Administration.FDA approves first treatment for post-partum depression.
Azhar Y, Din AU.Brexanolone.
StatPearls Publishing; 2020.
Michigan Medicine, University of Michigan.Brexanolone.
2019;15(2):2-4. doi:10.1177/0897190020979627
U.S. National Library of Medicine.Zulresso- brexanolone injection, solution.
